XML 35 R19.htm IDEA: XBRL DOCUMENT v3.20.4
Note 13 - Revenue by Product Group, by Significant Customer and by Geographic Location; Geographic Information
12 Months Ended
Dec. 31, 2020
Notes to Financial Statements  
Revenue from Contract with Customer [Text Block]

13. Revenue by Product Group, by Significant Customer and by Geographic Location; Geographic Information

 

The Company categorizes its product portfolio into three product families: Joint Pain Management, Joint Preservation and Restoration, and Other. Anika’s consolidated financial statements include results of operations for Parcus Medical from the January 24, 2020 acquisition date and Arthrosurface from the February 3, 2020 acquisition date.

 

      Product revenue by product group is as follows:

 

  

Years Ended December 31,

 
  

2020

  

2019

  

2018

 
  

Revenue

  

Percentage of
Product
Revenue

  

Revenue

  

Percentage of
Product
Revenue

  

Revenue

  

Percentage of
Product
Revenue

 

Joint Pain Management

 $83,029   64

%

 $103,466   90

%

 $96,719   92

%

Joint Preservation and Restoration

  39,368   30

%

  2,070   2

%

  1,127   1

%

Other

  8,060   6

%

  8,976   8

%

  7,685   7

%

  $130,457   100

%

 $114,512   100

%

 $105,531   100

%

 

Product revenue from the Company’s sole significant customer, Mitek, as a percentage of the Company’s total product revenue was 49%, 71%, and 73% for the years ended December 31, 2020, 2019, and 2018, respectively.

 

Total revenue by geographic location based on the location of the customer in total and as a percentage of total revenue are as follows:

 

  

Years Ended December 31,

 
  

2020

  

2019

  

2018

 
  

Total

  

Percentage of

  

Total

  

Percentage of

  

Total

  

Percentage of

 
  

Revenue

  

Revenue

  

Revenue

  

Revenue

  

Revenue

  

Revenue

 

Geographic Location:

                        

United States

 $103,182   79

%

 $90,302   79

%

 $85,351   81

%

Europe

  14,179   11

%

  14,744   13

%

  11,730   11

%

Other

  13,096   10

%

  9,564   8

%

  8,474   8

%

Total

 $130,457   100

%

 $114,610   100

%

 $105,555   100

%

 

On May 2, 2018, the Company publicly disclosed a voluntary recall of certain production lots of its HYAFF-based products, Hyalofast, Hyalograft C, and Hyalomatrix. The Company initiated the voluntary recall after internal quality testing, which indicated that the products were at risk of not maintaining certain measures throughout their entire shelf life. While there was no indication of any safety or efficacy issue related to the products at the time, the Company removed the products from the field as a precautionary measure. In 2018, the Company recorded a revenue reserve for this voluntary recall of $1.1 million of which $0.9 million was related to revenue recorded in prior periods. The revenue reserves impacted Joint Preservation and Restoration and Other product groups and all geographic locations. There was no remaining revenue reserve as of December 31, 2020 and 2019.

 

Net long-lived assets, consisting of net property and equipment, are subject to geographic risks because they are generally difficult to move and to effectively utilize in another geographic area in a reasonable time period and because they are relatively illiquid. Net tangible long-lived assets by principal geographic areas are as follows:

 

  

Years Ended December 31,

 
  

2020

  

2019

 

United States

 $48,611  $48,635 

Italy

  2,002   2,148 

Total

 $50,613  $50,783